<SEC-DOCUMENT>0001193125-23-025715.txt : 20230206
<SEC-HEADER>0001193125-23-025715.hdr.sgml : 20230206
<ACCEPTANCE-DATETIME>20230206170428
ACCESSION NUMBER:		0001193125-23-025715
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20230206
FILED AS OF DATE:		20230206
DATE AS OF CHANGE:		20230206

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			IMMUTEP Ltd
		CENTRAL INDEX KEY:			0001506184
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			C3
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-35428
		FILM NUMBER:		23591432

	BUSINESS ADDRESS:	
		STREET 1:		LEVEL 12, 95 PITT STREET
		CITY:			SYDNEY, NEW SOUTH WALES
		STATE:			C3
		ZIP:			2000
		BUSINESS PHONE:		612 9276 1224

	MAIL ADDRESS:	
		STREET 1:		LEVEL 12, 95 PITT STREET
		CITY:			SYDNEY, NEW SOUTH WALES
		STATE:			C3
		ZIP:			2000

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Prima BioMed Ltd
		DATE OF NAME CHANGE:	20101119
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>d274965d6k.htm
<DESCRIPTION>6-K
<TEXT>
<HTML><HEAD>
<TITLE>6-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM 6-K
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>REPORT OF FOREIGN PRIVATE ISSUER </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PURSUANT TO RULE 13a-16 OR 15d-16 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>UNDER THE SECURITIES EXCHANGE ACT OF 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Dated February 6, 2023 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Commission File Number 001-35428 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>IMMUTEP
LIMITED </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact Name as Specified in its Charter) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>N/A </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Translation of
Registrant&#146;s Name) </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Level 33, Australia Square </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>264 George Street, Sydney </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NSW 2000, Australia </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive office) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether
the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Form
20-F&nbsp;&nbsp;&#9746;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Form 40-F&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the
registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant
is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether by furnishing the
information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule&nbsp;12g3-2(b) under the Securities Exchange Act of 1934. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Yes&nbsp;&nbsp;&#9744;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;&#9746; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If &#147;Yes&#148; is marked, indicated below the file number assigned to the registrant in connection with Rule 12g3-2(b): Not applicable. </P>
<P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT INDEX </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="94%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Exhibit</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Description&nbsp;of&nbsp;Exhibit</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">99.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><A HREF="d274965dex991.htm">Immutep Reaches Enrolment Target for INSIGHT-003 Trial in 1st Line NSCLC </A></P></TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dated: February 6, 2023 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">IMMUTEP LIMITED</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Marc Voigt</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Marc Voigt</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Chief Executive Officer</TD></TR>
</TABLE></DIV>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d274965dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g274965dsp11.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ASX/Media Release </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Immutep Reaches
Enrolment Target for <FONT STYLE="white-space:nowrap">INSIGHT-003</FONT> Trial in 1<SUP STYLE="font-size:75%; vertical-align:top">st</SUP> Line NSCLC </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">20 patients with 1st line <FONT STYLE="white-space:nowrap">non-small</FONT> cell lung cancer (1L NSCLC) now
enrolled in the first triple combination therapy study of efti with <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">standard-of-care</FONT></FONT> combination of
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-1</FONT></FONT> therapy and chemotherapy </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Promising initial efficacy results showing a 72.7% response rate and 90.9% disease control rate reported at SITC
2022 </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Additional data is expected throughout calendar year 2023 and will further inform our next steps in 1L NSCLC
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SYDNEY, AUSTRALIA &#150; 6</B><B></B><B>&nbsp;February </B><B>2023 &#150;</B> <U>Immutep Limited</U> (ASX: IMM; NASDAQ: IMMP)
(&#147;Immutep&#148; or &#147;the Company&#148;), a clinical-stage biotechnology company developing novel <FONT STYLE="white-space:nowrap">LAG-3</FONT> immunotherapies for cancer and autoimmune diseases, today announces the investigator-initiated <FONT
STYLE="white-space:nowrap">INSIGHT-003</FONT> trial has reached its enrolment target of 20 patients with 1L NSCLC. <FONT STYLE="white-space:nowrap">INSIGHT-003</FONT> is the first trial evaluating Immutep&#146;s lead product candidate, eftilagimod
alpha (&#147;efti&#148; or &#147;IMP321&#148;) as part of a triple combination therapy with <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">standard-of-care</FONT></FONT> <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">anti-PD-1</FONT></FONT> therapy and chemotherapy. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Immutep&#146;s CSO&nbsp;&amp; CMO Dr Frederic Triebel said,<I> </I>&#147;The
promising initial efficacy and favourable safety results reported in November 2022 from this first triple combination approach instils more confidence in the flexibility of our novel immunotherapy, efti, to be combined with various therapeutics and
safely drive superior patient outcomes. We are pleased to have reached our enrolment target and look forward to reporting as the results mature further. Additional data from <FONT STYLE="white-space:nowrap">INSIGHT-003</FONT> will help further
inform our next steps in 1<SUP STYLE="font-size:75%; vertical-align:top">st</SUP> line NSCLC.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In a poster presented at the Society for
Immunotherapy of Cancer (SITC) Annual Meeting 2022, initial results in 1L NSCLC patients show the triple combination therapy is well-tolerated and provides promising early signals of therapeutic activity with an Objective Response Rate (ORR) of
72.7% (8/11) and a Disease Control Rate (DCR) of 90.9% (10/11). Nine patients had a <FONT STYLE="white-space:nowrap">PD-L1</FONT> Tumour Proportion Score (TPS) of &lt;50% and this group reported an encouraging ORR of 66.7% and DCR of 88.9%. Patients
with a <FONT STYLE="white-space:nowrap">PD-L1</FONT> of &lt;50% represent approximately <FONT STYLE="white-space:nowrap">two-thirds</FONT> of the 1L NSCLC patient population and are less responsive to <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">anti-PD-1</FONT></FONT> therapy compared to patients with a <FONT STYLE="white-space:nowrap">PD-L1</FONT> TPS of &#8805;50%. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Additional data from <FONT STYLE="white-space:nowrap">INSIGHT-003</FONT> is expected to be presented throughout calendar year 2023. For more information on
the study, please see the poster titled <I>&#145;</I><I>Feasibility of eftilagimod alpha (soluble <FONT STYLE="white-space:nowrap">LAG-3</FONT> protein) combined with
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">standard-of-care-therapy</FONT></FONT> in advanced <FONT STYLE="white-space:nowrap">non-small-cell</FONT> lung cancer (NSCLC). Initial results from INSIGHT 003&#146;</I> in the
<U>Posters&nbsp;&amp; Publications</U> section of Immutep&#146;s website. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g274965dsp11.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About <FONT STYLE="white-space:nowrap">INSIGHT-003</FONT> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">INSIGHT-003</FONT> is an investigator-initiated study conducted by the Institute of Clinical Cancer Research IKF at
Krankenhaus Nordwest in Frankfurt. It is being run as the third arm (Stratum C) of the ongoing Phase I INSIGHT trial with Prof. Dr.&nbsp;Salah-Eddin Al-Batran as lead investigator. The study is evaluating a triple combination therapy in front line <FONT
STYLE="white-space:nowrap">non-small</FONT> cell lung cancer patients consisting of efti administered subcutaneously in conjunction with an existing approved
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">standard-of-care</FONT></FONT> combination of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-1</FONT></FONT> therapy (pembrolizumab) and chemotherapy
(carboplatin and pemetrexed) delivered intravenously. The trial will assess the safety, tolerability, and initial efficacy of the combination. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About
Immutep </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Immutep is a clinical stage biotechnology company developing novel <FONT STYLE="white-space:nowrap">LAG-3</FONT> immunotherapy for cancer and
autoimmune disease. We are pioneers in the understanding and advancement of therapeutics related to Lymphocyte Activation <FONT STYLE="white-space:nowrap">Gene-3</FONT> <FONT STYLE="white-space:nowrap">(LAG-3),</FONT> and our diversified product
portfolio harnesses its unique ability to stimulate or suppress the immune response. Immutep is dedicated to leveraging its expertise to bring innovative treatment options to market for patients in need and to maximise value for shareholders. For
more information, please visit <U>www.immutep.com</U>. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Australian Investors/Media: </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Catherine Strong, Citadel-MAGNUS </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">+61 (0)406 759 268;
<U>cstrong@citadelmagnus.com</U> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>U.S. Investors/Media: </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Chris Basta, VP, Investor Relations and Corporate Communications </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">+1 (631) 318 4000; <U>chris.basta@immutep.com</U> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This
announcement was authorised for release by the Board of Immutep Limited. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Immutep Limited</B>, Level&nbsp;33, Australia Square, 264
George Street, Sydney NSW 2000, Australia </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ABN: 90 009 237 889 </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g274965dsp11.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g274965dsp11.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M P$  A$#$0 _ /OZ@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
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MSHM3T9\O&M&;Y9J[9ZY%\']#CTQ[=I+LSN@#S"4KN(_V>F,^U=2PZ2O<]B.
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M6R2CHCLI48T5:*-JF:G"_%WCP-?8_P">D7_HP5E7_ALXLP_@,XGX%\7^L?\
M7*/^9K#"'#E/VC#^,''C:;M^XC_D:SKV4M3ES5?O[>1W^A?"WPY?>'[">>UD
M,]Q;H[2"5L@E03CM71&A!H].C@J,Z46T>.^+-!;PSKMWII8R)"08W;J4/(S[
MX_E7-*FHNQY&)I*E-Q/9=,^$WAJ32X6:"XE>:-6\YI2&&1VQ@?I77&@K:GLP
MR^BXIOL>.7]M-X,\4RQ0N3-I]P&C?N0""/S&,UQ-.G,\:HGAZUH=#Z$\;R>9
MX)UEP.&M&8?E7?5^ ^AQ'\"7H>)?#/PW8>)]<FM-6C=X8X#( K%>=P';ZUQT
M*:E+4\/ T8U9\LCK_B%\,M+TK0Y-3T5)();8J70N65E)QWSSS6M2C&,+HZ\7
M@:=*GSP.4^&'A;3O%6J7,.K><4MXA(J(^T/S@[OSK&A",Y.YS9?0A4FU(Z7X
MD?#?3M$T9M5T)'A\A@LL;.64J3C(ST()%;5*$81]TZ,9@H4Z;G#H6O@=JD\B
M:IITK$PQ;)HQ_=SD$?F*,-/H5E=1R4EZ?J>9_M%8'Q CX_YA\?\ Z$]=9[!]
M!_#'_DGWAO\ Z\H_Y4 >%?M+\>,-(_[!_P#[4:@#U_X)?\DP\/\ ^Y)_Z->@
M#YD\(:':^)?']EI.HAS:W5TZR>6VUL88\'\* /H,_LZ^#,$;=1(/&/M/_P!:
M@#HOB7XED\!^![F\TY0;A%2VMRW9F^4,?H,G\* /G;X3_#H?$;6KRXUBYD^P
M6I$EP0W[R9F)P,_@230!Z[XY^!GAN3P]=S^';,V.H6D32QE)6*R%1G:X)/7'
M6@#S[]G;Q7-IWB:70'YM=10NHS]R1!G./=0<_04 4OVB,CXA#L?L,7;W>@#T
M?P7\&/"&M>#-'O;ZQG>[O+2.5Y1<.I#$9) !P.OI0!Y7\6?A>/AU=6=UIEU)
M-IMTQ$7FD>9"Z\XR.OJ#0![_ /!WQ9)XL\%V<MX[/?6;&VN';J[+T8^Y!!/O
M0!Z!C% !0 4 <+\7O^1&OO\ KI%_Z,%95_X;.+,/]W9Q/P+_ .0AK'_7*/\
MF:PPAPY3]HQ/C!QXVF_ZX1_R-9XC<Y\R=L1IV/<_"O'AG1O^O.+_ - %=L%:
M*/=H?PXGA7Q>7'C>YQWAC_\ 0:X:[M*QX691YJ[_ *Z'O>B?\@;3O^O>/_T$
M5WQT21[U'X%\CYV^)XV^-]7QZI_Z M>?B'[Y\]F"7MY'MWBX_P#% :E_UXG_
M -!KNJ_ >[B'^XEZ'EOP2&?$]U_UZ'_T):YL,[2/)RMOVK]'^9ZG\1ACP5K/
M/_+(?^A"NBLE[-GIXZ_U>2/,?@>,:_J'/'V3_P!F6N7"I<QYN4W51KR/2OB8
MN/ NKC_87_T-:ZJ_PGIX[6A+Y?F>>? LYU75O3R(_P#T)JY\+J>?E7Q279(X
M3]HU67X@09! :PCP?7YGKM/;/?/A5<QW'PZ\./"2RBT5#@="ORG]0: /$/VF
M/^1QTC_L'_\ M1J /7_@GQ\+] P.D<G'_;5Z /G7X9,$^+6CACC_ $N09/3.
MUAC\Z /LR@#R3]HN-V^'\;(.([Z(M^(8#]2* /#/AQ\.+CX@_P!H+9:O#926
MFPF.2,L7#9&1]",?C0!WO_#-6K#IXCMOQ@8_UH W_ WP(OO"/BO3=:GUBVFB
MLV8F*.%E+90KU)_VLT >??M$#'Q" ]+&+^;T ?1/PSX^'WAD>FGP_P#H(H \
MW_:9FC3PYHL+%1(]Z64'K@1MD_J/TH 7]F:VEC\.ZU.^?)FO $SW(09Q^8_*
M@#W&@ H * .%^+W_ "(U]_UTB_\ 1@K*O_#9Q9A_N[.)^!?_ "$-8_ZY1_S-
M880X<I^T8GQ@P/&TV>/W$?\ (UGB-SGS/_>/D>Y^%O\ D6=&Q_SYQ?\ H KN
MC\*/=H?PXGA/Q?)'C>Y_ZX1_^@UY^(^-GB9A_'9[YHG_ "!=._Z]X_\ T$5Z
M*V1[E#^&CYV^*) \;:OD]T_] 6O-K_&?/8_^/(]N\6X'P_U//_/C_P"RUWU?
M@/<Q'^[R]#R[X(D?\)1=8/\ RZ-_Z$M<N'^(\K*OXK]'^9ZG\1^/!&L^T0_]
M"%=-7^&SU,=_ GZ'E_P.8'Q!J&#_ ,NI_P#0DKFPOQ,\S*?XC]#TWXF?\B-J
M_P#N+_Z&M=-?X&>GC?\ =Y?+\SSKX%?\A75O^N"?^A&N?"GGY3_$GZ(F^/\
MX$U#Q!9Z=J^AVDES<V8:.>.,98QG#!@.^"#TYYKM/;/)_ ?QCUCP'I\FG0V\
M%Y9[RR1S$@PL>H!';V- &-\0?'EU\0=6MK^^MH+:2"'R%CB)/R[B<G/?F@#Z
M>^#,4EO\,]!CE0HZI)\K @_ZUO6@#YK^(/AS4_ ?C6[F59H$-T;FRNU4A6!;
M<,-TR.A'MTH [63]I77S8^7'I>GI<A=OGEF.3CKMZ9H ]SNM-@^(/@2&VU,E
M4U2SCD9@O*,55@1[@XH ^4;K3/$_PI\1Q7$JS6%Q$Y$-P!F.=0<<=F!'\)]:
M /0%_:8UI85#:)8-)CEA(X'Y?_7H ]%^#'C_ %3QY#KD^MF,-;3((DBCVJBL
M&^7WZ=^: /(?VB<#X@\\#[#%_-Z &^%/COK_ (1TB#29+.TNX;:-4A\[<C(@
M'R@XZC% ',ZOK/B3XL>)#(L$MW=.-L5K I*6Z_T'JQ_&@#ZW\"^&E\(>&--T
M<,KO;Q_O748#.268_F3^ % '24 % !0!#/#%<(8[B))(SU5U!!H 9!8V]KDV
MUM%$3U\M ,_E0 R;3K.Z??<6L$K?WGC#'^5 %B/9$H1 J!> HXQ0!7FTZSN'
M,EQ:02/_ 'G0$_GB@"RBJJA4 "KP .,4 5Y=-LYY#)/:6\DC=6>($G\: )7B
MCDC\IT!0C&PC((^E $,-C:6C[[:WAB;&"415_4"@":2))8RDRJZMU5AD'\*
M&6]C:6KE[6WAB8C!*(%)_(4 /N(8IXS'.BNAZJP!!_ T ,MK*VM#_HUO%"3P
M2B!<_E0!.6&!_7B@#!O_  5X;U68SZGH6FW,QY,DMJC,?J<9H DL/"/A_2G$
MFF:'IUM(#PT-LBD?B!0!MCCZ4 5;_3K/5+=H-2M8+FW8\QSH'7\CQ0!CVG@7
MPOITRS67A_2X90<ADM4!'XXH Z$%5  P,=J *][96NHV[VU_;17%NXPT<R!E
M/U!&* .?7X=>$$;?%X:T@,#U^R1]?RH Z.UMX+.%8;2&.&)> D:A0/P% 'RI
M^T3Q\0_^W&+^;T >X^"?#.C:[\/_  LVM:397C+I\.#<0K(?N#N10!V.F:)I
MNB1&+1]/MK2,]5MXEC!_(4 :% !0 4 % &%XJO)[*SLFM9&C9[^VB)4XRK3*
MK#\B: +>M:K'I&E7=Y)MVPQDKE@ S=%7ZDX'XT 87A#5,R76D7>K#4KRU"S?
M:0RGS$?J1CT8,/8;: %TB<'2M-U75=2N6GOI$8!)"$4R'Y8M@XP,XSUR,T ;
MJZE#=7%Q8HMU'+&OS2>2ZJ,]U<C:3]#0!E>&[FY.J:K;7$5U!'$(C'%=2B1B
M#N&\-D\-MZ9X*GI0!+X@N[BVUCPS%;S-''<WKQRJ.CJ()6 /XJ#^% '.)XPN
MM+UO7FU!+BXT[[2UM:)&H.R5(4;RQC^^6(&?XEQWH ECU+5Y/"OB3[1=F+5;
M>X>%9$PP@9U1E"\<A?, YZX]Z "Z\07T=E:V4=VO]HZ=.O\ :+@#+(DBCE>W
MF!@1[;L=* .F>ZF'B6&VWMY+6C/L[;@ZC/Y?SH P=:O[\>$;J:TO9(+LZB;>
M.< $JIO/+'!Z@+@8]!VH T=/UM[_ %>WM)66*YA@G6ZMT;(5U>,*W/.""2I]
M#0!EZ=+<Z[H>H:K)J%Q:7 EG\E$<JEN(W95#+T/W-QR,\T 2ZM>7%YX0L-8C
MDN+.YGCMG,22,NWS'0$$>H#$4 :FL2W&BQZ6+%;NZ+7>QH1("\@,;G&7([@'
MKVH @T#5;S4-?UB&]M[BUB@BMS';SE"5)\S+#:2.<#OVH C\&SW5W9VMQ>6V
MI(\ELCM-<7"O'(2H)*J&)'Y"@#GM!U^[O+W3H8Y-4%X]Y<"9[A2+>6))) 0I
M(P2 !C;Z4 :WC'7+NRNHTTRZ@A>PB^VRQ2.H-T,X$(![L!)T[A: '^*-<\D>
M&I;>2Z-G?W!\P6:.SR)Y,CJ $YQE1TH 721KUQHEZ\C7"W,=V9+%;K"220@J
M0DF!QGYER>>A- &MX;N;S4[=]4NPT,%X%>VMB03''C(+?[39SCL,#L: /FK]
MHD8^(0_Z\8OYO0!]#_#/_DGWAC_L'P_^@B@#JZ "@ H * "@"IJ&GV^I6_D7
ML9>,,K@!BI#*<@@CG@@4 1#2;1HHXI4DE1)5F7SY7<AU.0<L2>"* )7TZWDO
MHKUXU^TPHT:2=PK$$K],@?E0!4'A[3TE61(&4)+YZQK*XC#YSNV9VYS[4 :,
MT*31-&X.&&"5)4_@1R* (+/3;:RDDD@5_-D #/)(TC$#.!EB3@9/'N: 'W%C
M!=3VLT\8:2U<R1$_P,5*Y'X,1^- $=OI=I:^>(8$433&X<8ZR''S?7@?E0 W
M^R+,+=*(%VW4HFF']]P% )_!%_(4 .N=+L[Q;A+BVB;[0 LIVX,@'0$]\4 -
MO-)MKYHGN$<RQ JDD<C(R@]1E2#@X''L* &_V-8_8([ 6Z"UB962/L"K!@?K
MN /UH F:PMFO5OO)3[6D9A$N/FVDYQGTS0!4G\.:;<23M+;Y%P=TR+(RI*<8
MRR@X;\1S0!=N[*"]MS!<H'B)#;3TX((_4"@!TUM'.T+3*&:%_,0GLV",_D30
M U+.&*[FNDC GF54D?\ O!<[?RW'\Z *]EH]KIY3[+YX6-=BHUQ(ZJ/0*210
M #1K%;:*V6!5AAE\] "1M?=NW#WR3^= %B"Q@MY[B:% )+A@TC9SN(  _( 4
M 01Z+91K9*D"A;%BT [1D@KQ^#$?C0!>( '3% #+:VCM+>*W@4)%"H1%'0 #
M % '.ZY\/_#?B2^-]KFD0W5T%$?F.6SM&<#@^YH W=.L+?2K*WLK")8;6W01
4Q1KG"*. .: +5 !0 4 % !0!_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
